Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15027430 | 1.00 | USP2 (0.53) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL31540500 | 1.00 | USP2 (0.53) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL27039953 | 1.00 | USP2 (0.53) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL31438712 | 1.00 | USP2 (0.53) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL4012822 | 1.00 | USP2 (0.53) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL10081536 | 1.00 | USP2 (0.53) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL10081314 | 0.97 | USP2 (0.50) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL9133230 | 0.93 | USP2 (0.49) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL8971074 | 0.89 | USP2 (0.43) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL14919581 | 0.89 | TSHR (0.67) | USP2ALDH1A1MAPTCYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788006-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4674856-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4635481-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3254672-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4218722-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12343398-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025077836-A1 | IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | WO | disclosed |
| US-12239709-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-2788006-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2575764-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120027803-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011153493-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011153493-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027803-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | USP2 3028/4885ALDH1A1 2749/4885MAPT 3579/4885 |
| US-12343398-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | USP2 3188/4885ALDH1A1 3151/4885MAPT 3534/4885 |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | USP2 3188/4885ALDH1A1 3151/4885MAPT 3534/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | USP2 3188/4885ALDH1A1 3151/4885MAPT 3534/4885 |
| US-12239709-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | USP2 3188/4885ALDH1A1 3151/4885MAPT 3534/4885 |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | USP2 3188/4885ALDH1A1 3151/4885MAPT 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.